Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

19

Revenue 2017

Keytruda

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Keytruda was produced by Merck & Co..

Newly-listed BioNTech buys Neon to boost cell therapy assets

Newly-listed BioNTech buys Neon to boost cell therapy assets who are not responding to treatment with checkpoint inhibitor drugs like Bristol-Myers Squibb’s Opdivo (nivolumab) and Merck &Co’s Keytruda (pembrolizumab).

FDA starts priority review of BMS Opdivo/Yervoy in first-line NSCLC

FDA starts priority review of BMS Opdivo/Yervoy in first-line NSCLC If approved, BMS will finally have a regimen that can challenge its main rival in the PD-1 inhibitor category – Merck &Co/MSD and its Keytruda (pembrolizumab) product – which has dominated ... The FDA’s review will focus on the CheckMate-227 trial,

Pfizer signs $507m cancer deal with Effector Therapeutics

Pfizer signs $507m cancer deal with Effector Therapeutics 1 inhibitor Keytruda(pembrolizumab).

Keytruda claims first place in bladder cancer race

Keytruda claims first place in bladder cancer race Stays ahead of rivals in the PD-1/PD-L1 inhibitor class. Merck &Co’s Keytruda has become the first PD-1/PD-L1 inhibitor to get approval in the US ... Merck is also running a phase 3 trial called Keynote-676 trial to confirm Keytruda’s activity in

Keytruda doesn’t extend survival in small cell lung cancer

Keytruda doesn’t extend survival in small cell lung cancer Unlikely to extend use into the first-line setting. Merck &Co has reported mixed results from a phase 3 trial of its cancer immunotherapy Keytruda, as it tries to extend the ... The results of the KEYNOTE-604 trial show that when Keytruda (pembrolizumab)

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

OPEN Health’s response to the FDA’s guidance on long term follow up post gene therapy
OPEN Health’s response to the FDA’s guidance on long term follow up post gene therapy...
Cannes or Canned
Creating a culture where innovation thrives
It starts with us...
David Atkins
A snapshot of Congenica
PME talks to CEO David Atkins...

Infographics